



Investment Objective

To achieve consistent and above average capital appreciation over the medium to long-term by investing in companies with market capitalization of not more than RM750 million at the time of acquisition.

Investor Profile

The fund is suitable for investors who are willing to accept higher level of risk in order to obtain higher growth of their capital and have a medium to long term investment horizon.

Fund Manager

UOB Asset Management (Malaysia)

Fund Details


Unit NAV	RM3.8982
Fund Size	RM81.5 million
Inception Date	1 April 2005
Management Fee	1.50% per annum

Top 10 Holdings

D&O Green Technologies	7.5%
Formosa Prosonic	6.6%
Dufu Technology	6.5%
Frontken	4.9%
Pentamaster	4.8%
Kobay Tech	4.7%
Thong Guan	4.5%
Duopharma Biotech	4.0%
Genetec Technology	3.5%
Able Global	3.5%

Data as at 31 January 2022

Cumulative Performance Since Inception as at 31 January 2022




Performance Table as at 31 January 2022

	1 month	3 months	6 months	YTD	1 year	3 years	5 years	Since inception
Fund	-10.7%	-12.7%	-1.9%	-10.7%	-0.3%	70.9%	75.4%	720.7%
Benchmark	-3.9%	-5.9%	-0.9%	-3.9%	-4.3%	-6.8%	-7.4%	85.4%

- Benchmark: FTSE Bursa Malaysia Emas Index
- Source: Bloomberg & Gibraltar BSN Life Bhd

Past performance is not indicative of future performance and the performance of the fund is not guaranteed.

Portfolio Composition as at 31 January 2022



Source: UOBAM



Manager's Comment

For January 2022, the Fund's NAV/unit decreased by 10.7%, underperformed the FBM EMAS which decreased by 3.9% mainly due to the Fund's underweight position in the industrial and technology sectors.

In January, global equities were weaker due to concerns of tighter US Fed policy, Omicron outbreaks in Asia and geopolitical tension in Ukraine. The US Fed signalled it would begin to raise interest rates as early as March 2022 as US inflation is well above the 2% mark and its labour market remains robust.

On the domestic front, the FBM KLCI Index declined 3.5% to close at 1,512 points due to rising global interest rates expectations. Among sectors, the laggards were technology, healthcare and telecommunications. As inflationary pressure persists, expectations of an accelerated rate hike cycle led to a sell-down of equities with growth sectors like technology hit harder. However, earnings outlook remained positive on strong secular trends and increasing supply chain diversion to the country.

In another development, Bank Negara Malaysia (BNM) maintained the overnight policy rate at 1.75%. BNM's monetary policy committee commented that risk to growth outlook remained tilted to the downside amid uncertainties of potential new variants, supply chain disruptions and weaker than expected global growth.

We would adopt a barbell strategy and target to have a balanced exposure in both growth and value sectors. For growth exposure, we prefer the technology and industrial sectors. As for value/reopening, we focus on consumer and commodities.

Disclaimer

This report is for information only and is purely a product summary. Please refer to the product fact sheet available at www.gibraltarbsn.com for further details. This report shall not be reproduced, copied, circulated or forwarded either in part or otherwise to any persons howsoever without the prior written consent of Gibraltar BSN Life Berhad.

The opinions and information contained herein are based on the latest available data which is believed to be reliable. It is not to be construed as an offer, invitation or solicitation to buy or sell any securities or financial instruments covered by this report. Gibraltar BSN Life Berhad does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall give rise to any claim whatsoever against Gibraltar BSN Life Berhad and/or its associated persons. Gibraltar BSN Life Berhad and/or its associated persons may from time to time have an interest in the securities or financial instruments mentioned by this report. Past Performance of the Funds mentioned in the Report is not an indication of its future performance. Investors/policy holders should rely on their own evaluation to assess the merits and risks of the investment. In considering to invest in an investment-linked fund, investors/policy holders who are in doubt on the action to be taken should consult a professional adviser. Investors/Policy holders have to take note that investments can fluctuate in value and values may fall as well as rise and an investor/policy holder may not get back the amount invested.